What is the cure rate of Epclusa (sofosbuvir/velpatasvir) for hepatitis C?
Epclusa’s “cure rate” is usually reported as the percentage of people who achieve a sustained virologic response 12 weeks after finishing treatment (SVR12), meaning the virus is no longer detectable and the infection is considered cured [1].
Cure rate by hepatitis C type (genotype)
Across clinical trials of Epclusa for hepatitis C, SVR12 rates were consistently high across genotypes, including people with genotype 1 through 6 infection [1].
How long is treatment, and how does that affect cure rate?
Epclusa is taken once daily for 12 weeks in the standard regimen used in many trials, and SVR12 rates were reported after that course [1]. In general, shorter or longer-than-standard approaches are less common; cure rates are still best described using SVR12 from the specific study regimen.
What changes the cure rate for patients (real-world factors people ask about)?
SVR12 (cure rate) can vary based on factors that clinical studies account for, including prior treatment experience, presence of cirrhosis, and baseline viral characteristics. Epclusa trials reported high cure rates across major subgroups, but individual results depend on a patient’s situation [1].
If Epclusa doesn’t cure, what happens next?
When treatment fails, clinicians typically reassess prior regimens used, genotype/subtype, resistance considerations, and cirrhosis status to choose an effective salvage regimen. “Not cured” in these studies is usually defined by not achieving SVR12 (ongoing detectable virus) [1].
Sources
[1] https://www.epclusa.com/